← Back to Search

Multispectral + High-Resolution Microendoscopy for Oral Cancer

Phase < 1
Recruiting
Led By Ann Gillenwater
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at using different colors of light to get a better look at mouth lesions during surgery, which may help doctors better identify which ones are pre-cancerous or cancerous.

Who is the study for?
This trial is for adults with oral lesions who are already scheduled for surgery to remove or biopsy these areas. Participants must understand and be willing to sign a consent form. It's open to those who've had previous treatments.
What is being tested?
The study tests imaging techniques like wide-field and high-resolution in vivo imaging, using multispectral lights and proflavine dye, to better visualize mouth lesions during surgery and assess their cancer risk.
What are the potential side effects?
Potential side effects may include mild discomfort from the imaging process or reactions to the proflavine dye such as local irritation. However, detailed side effect profiles will depend on individual patient responses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Classification of tissue
Evaluation of oral mucosa to be used for non-invasive detection and diagnosis with the use of optical imaging after administration of the topical contrast agent proflavine.
Secondary study objectives
Percentage of subjects and lesions that can be successfully imaged with wide-field and high-resolution optical microscopes after topical application of contrast dye
Qualitative features within images that differ between pathologically normal, dysplastic, cancerous and inflammatory lesions

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (widefield multispectral imaging and HRME)Experimental Treatment3 Interventions
Patients undergo evaluation of oral cavity using a widefield multispectral imaging device and a high-resolution optical system (HRME) at baseline, after induction of general anesthesia, and prior to surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Proflavine
2015
Completed Phase 2
~100

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,928 Previous Clinical Trials
41,017,864 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
3,068 Previous Clinical Trials
1,802,404 Total Patients Enrolled
Ann GillenwaterPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
63 Total Patients Enrolled

Media Library

Multispectral Imaging Clinical Trial Eligibility Overview. Trial Name: NCT01269190 — Phase < 1
Mouth cancer Research Study Groups: Diagnostic (widefield multispectral imaging and HRME)
Mouth cancer Clinical Trial 2023: Multispectral Imaging Highlights & Side Effects. Trial Name: NCT01269190 — Phase < 1
Multispectral Imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT01269190 — Phase < 1
~20 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top